(Q37923968)

25 August 2017

1 reference

title

Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient? (English)

1 reference

25 August 2017

1 reference

2

1 reference

25 August 2017

1

Gerald F Watts

1 reference

25 August 2017

1 August 2011

1 reference

Expert Review of Cardiovascular Therapy

25 August 2017

1 reference

25 August 2017

9

1 reference

25 August 2017

8

1 reference

25 August 2017

987-997

1 reference

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

25 August 2017

1 reference

Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation

21 January 2018

1 reference

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

21 January 2018

1 reference

Diabetic dyslipidaemia: from basic research to clinical practice.

21 January 2018

1 reference

Clinical practice. Hypertriglyceridemia

21 January 2018

1 reference

Triglycerides are more important in atherosclerosis than epidemiology has suggested

21 January 2018

1 reference

How independent are "independent" effects? Relative risk estimation when correlated exposures are measured imprecisely.

21 January 2018

1 reference

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

Postprandial lipemia and remnant lipoproteins

21 January 2018

1 reference

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

21 January 2018

1 reference

Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus

21 January 2018

1 reference

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

21 January 2018

1 reference

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population

21 January 2018

1 reference

Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance

21 January 2018

1 reference

Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies

21 January 2018

1 reference

Atherogenesis: a postprandial phenomenon

21 January 2018

1 reference

Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall--evidence that plaque cholesterol may be derived from post-prandial lipoproteins.

21 January 2018

1 reference

Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase

21 January 2018

1 reference

Leukocyte activation by triglyceride-rich lipoproteins

21 January 2018

1 reference

Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation

21 January 2018

1 reference

Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes.

21 January 2018

1 reference

The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial

21 January 2018

1 reference

Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins.

21 January 2018

1 reference

21 January 2018

Standard lipid profile

1 reference

Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study

21 January 2018

1 reference

Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events

21 January 2018

1 reference

Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.

21 January 2018

1 reference

21 January 2018

When is equal not equal?

1 reference

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

21 January 2018

1 reference

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial

21 January 2018

1 reference

Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease

21 January 2018

1 reference

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis

21 January 2018

1 reference

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial

21 January 2018

1 reference

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells

21 January 2018

1 reference

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

21 January 2018

1 reference

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial

21 January 2018

1 reference

Effects of medical therapies on retinopathy progression in type 2 diabetes

21 January 2018

1 reference

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

21 January 2018

1 reference

21 January 2018

1 reference

Safety considerations with fibrate therapy

21 January 2018

1 reference

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).

21 January 2018

1 reference

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

Safety considerations with niacin therapy.

21 January 2018

1 reference

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

21 January 2018

1 reference

Effects of niacin on glucose control in patients with dyslipidemia.

21 January 2018

1 reference

N-3 polyunsaturated fatty acid regulation of hepatic gene transcription

21 January 2018

1 reference

An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia

21 January 2018

1 reference

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

21 January 2018

1 reference

n-3 fatty acids and cardiovascular events after myocardial infarction

21 January 2018

1 reference

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

21 January 2018

1 reference

OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction

21 January 2018

1 reference

Cardiovascular effects of marine omega-3 fatty acids.

21 January 2018

1 reference

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.

21 January 2018

1 reference

Methods to assess impaired post-prandial metabolism and the impact for early detection of cardiovascular disease risk.

21 January 2018

1 reference

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence

21 January 2018

1 reference

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment

21 January 2018

1 reference

Non-adherence to statin therapy: a major challenge for preventive cardiology

21 January 2018

1 reference

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association

21 January 2018

1 reference

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

21 January 2018

1 reference

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERC.11.61

1 reference

25 August 2017

1 reference

PubMed ID

21878044